BackIntellia Therapeutics Overview

Intellia Therapeutics Long Term Debt

Latest long-term debt for NTLA: $61M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$61.40M
23.72% YoYΔ $-19.09M vs prior year quarter

Peer average

Loading

Intellia Therapeutics Long Term Debt History

Loading

Intellia Therapeutics vs. peers: Long Term Debt Comparison

Loading

Intellia Therapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Intellia Therapeutics (NTLA) FAQ

As of the most recent data (March 2026), NTLA shows a long-term debt of $61M. That compares with $80M in the prior-year period — down 23.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NTLA's long-term debt is now $61M (was $80M) — a 23.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Intellia Therapeutics is outperforming or lagging.

Tracking NTLA's long-term debt over time shows whether Intellia Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $61M That compares with $80M in the prior-year period — down 23.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Intellia Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $61M) with ownership activity and broader fundamentals.

Intellia Therapeutics's long-term debt is $61M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.